Physician profile
Daniel Levitan
NPI 1164412946
$280.37
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.04 · 2020: $66.38 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $99.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $48.58 | 2019-2022 | |
| Amgen INC. | $38.86 | 2019-2020 | |
| Horizon Therapeutics Plc | $36.87 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.89 | 2019 | |
| Akebia Therapeutics INC | $21.28 | 2019 | |
| Getinge USA Sales, LLC | $11.90 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.